BIOASTER
Paul Anziani is a Research and Development Engineer at BIOASTER, focusing on metabolomics and proteomics since January 2023. Prior experience includes serving as a PhD student at Sanofi Pasteur from March 2019 to October 2022, where the thesis concentrated on multi-omics analyses of Bordetella pertussis for vaccine bio-production consistency monitoring. Additionally, Paul worked as a Fermenter Technician at Boehringer Ingelheim and completed several research internships, including contributions to optimizing ethanol production at Matís Iceland and identifying biomarkers in Multiple Myeloma patients at the Institute of Human Genetics. Paul Anziani holds a PhD in Biology from Université Claude Bernard Lyon 1, a Master's degree from the University of Montpellier, and a Bachelor's degree in Biology from Université de Nîmes.
This person is not in any offices
BIOASTER
1 followers
BIOASTER Technology Research Institute (TRI) is working to develop an unique technological and innovative model to support the latest challenges in microbiology, in particular to : -Fight antimicrobials resistance. -Improve vaccines safety and efficacy. -Quickly diagnose infections at patient bedside. -take full advantage to human and animal microbiota. In order to overcome technological bottlenecks and explore new avenues, BIOASTER is leading collaborative projects that bring together academics, start-ups, SMEs and industrial groups around key thematic and technology units. Each project strives on academic research excellence and is undertaken by a team of high-level experts and engineers, which benefits from state-of-the-art equipment, technological infrastructures. BIOASTER, an independent non-profit organization, is one of 8 French TRIs created in 2012 on the initiative of the French Government through the “Investments for the Future” program. The two historical founders are Lyonbiopôle (a biocluster, the one-stop shop for healthcare innovation in Rhône-Alpes, France) and the Institut Pasteur in Paris. They were joined from the beginning by the CNRS, the INSERM, the CEA, Mérieux Institute, Danone Nutricia Research and Sanofi Pasteur -and newly joined by bioMérieux- to create a unique Technology Institute dedicated to infectious diseases and microbiology in health. The Institute benefits from the support of Lyon Métropole and the Region Auvergne Rhône Alpes and the dynamism of a group of 40 SMEs in the Lyon and Paris regions. Located in Lyon and Paris, BIOASTER has more than 100 employees including 80 world-class scientists and engineers originating from 16 different countries. More information on www.bioaster.org